Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial

LESSONS LEARNED. Pazopanib was not effective in altering the premetastatic niche in the neoadjuvant setting. Pazopanib was safe and well tolerated without any new safety signals. BACKGROUND. Vascular endothelial growth factor receptor 1 (VEGFR1) expressing myeloid‐derived suppressor cells (VEGFR1+ M...

Descripción completa

Detalles Bibliográficos
Autores principales: Maughan, Benjamin L., Pal, Sumanta K., Gill, David, Boucher, Kenneth, Martin, Christopher, Salgia, Meghan, Nussenzveig, Roberto, Liu, Ting, Hawks, Josiah L., Batten, Julia, Nachaegari, Gayatri, Stephenson, Robert, Lowrance, William, Jones, Jeremy, Dechet, Christopher, Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292560/
https://www.ncbi.nlm.nih.gov/pubmed/30575560
http://dx.doi.org/10.1634/theoncologist.2018-0652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292560/
https://www.ncbi.nlm.nih.gov/pubmed/30575560
http://dx.doi.org/10.1634/theoncologist.2018-0652

Ejemplares similares